Sight Sciences

Sight Sciences is a medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease.

Sight Sciences develops technology-driven solutions that address the underlying physiology of ophthalmic diseases.

Sight Sciences was founded in 2018 by Paul Badawi and David Badawi. The company is headquartered in Menlo Park, California.

Sight Sciences was founded to change the way the practice of ophthalmology and optometry thinks about and treats the leading causes of eye disease.

Sight Sciences operates two business lines: surgical and non-surgical systems. Its surgical product portfolio consists of the OMNI™ Surgical System, for use by ophthalmologists. Its non-surgical product portfolio consists of the TearCare® System for use by ophthalmologists and optometrists.

 

TearCare is a software-controlled, wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to facilitate natural meibum expression when meibum is in its softened phase.

 

Sight Sciences is backed by D1 Capital Partners, KCK Group, MidCap Financial and others. The company raised $30M in a Series E round on 18, 2020. This brings Sight Sciences' total funding to $85.5M to date.

 

 

  • Year founded: 2018
  • Funding Info: $85.5M over 6 Rounds (Latest Funding Type: Series E)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Menlo Park
  • State: California
  • Country: United States
Related businesses